IBM Debuts Watson Clinical Imaging Review
IBM today introduced IBM Watson Imaging Clinical Review — the first cognitive imaging offering from Watson Health.
It also announced the expansion of the Watson Health medical imaging collaborative to 24 organizations worldwide, adding clinical and industry expertise for the worldwide initiative already tackling eye, brain, breast, heart and related conditions.
The Watson Health medical imaging collaborative is an initiative comprised of leading health systems, academic medical centers, private radiology practices, ambulatory radiology providers, and imaging technology companies that are finding ways to use medical imaging to identify and predict the risk of cancer, diabetes, and diseases of the eye, brain and heart and related conditions.
Watson Health will debut Watson Clinical Imaging Review, the first cognitive imaging offering from IBM. The offering reviews medical data including images to help healthcare providers identify the most critical cases that require attention.
The first application for the offering is cardiovascular disease, starting with a common condition called aortic stenosis (AS). AS, which affects 1.5 million Americans, occurs when the aortic valve in the heart is narrowed, impeding blood flow to the rest of the body and causing shortness of breath, tiredness, and chest pain.
A pilot study found that Watson Clinical Imaging Review was able to help hospital personnel identify potential AS patients who had not been previously flagged for follow up cardiovascular care.
Using Watson Imaging Clinical Review, hospital administrators may identify cases where follow up care is warranted and assure EMR information is complete. It uses cognitive text analytics to read structured and unstructured information in a cardiologist’s medical report, combines that with a variety of data from other sources (e.g. EMR problem list), and extracts relevant information to verify key data, including the diagnosis, is accurately reflected throughout the health record.
“Watson Imaging Clinical Review is the type of targeted AI-driven tool that providers could put to use to help them standardize care delivered across their organization, and gradually build a critical mass of reproducible results from their patient population. In doing so, it can support a population health-driven approach to personalized care,” said Nadim Michel Daher, a medical imaging and informatics analyst for Frost & Sullivan.
“Out of the gate, this type of cognitive tool may provide big benefits to hospitals and doctors, providing insights we don’t currently have and doing so in a way that fits how we work,” said Ricardo C. Cury, M.D., director of Cardiac Imaging at Baptist Health of South Florida and chairman and CEO of Radiology Associates of South Florida.
IBM plans to supplement the release of this offering with nine additional cardiovascular conditions, such as myocardial infarctions (heart attacks), valve disorders, cardiomyopathy (disease of the heart muscle), and deep vein thrombosis.
You can learn more about Watson Health here.